0001213809 Non-accelerated filer June 30, 2020 2020 Q2 false 140 Intracoastal Pointe Drive Suite 404 Jupiter Florida☒☐--12-31 us-gaap:ServiceMember us-gaap:ServiceMember us-gaap:ServiceMember us-gaap:ServiceMember P2Y P2Y P3Y P2Y P3Y P6M 0001213809 2020-01-01 2020-06-30 xbrli:shares 0001213809 2020-08-12 iso4217:USD 0001213809 2020-06-30 0001213809 2019-12-31 iso4217:USD xbrli:shares 0001213809 2019-04-01 2019-06-30 0001213809 2019-01-01 2019-06-30 0001213809 2020-04-01 2020-06-30 0001213809 us-gaap:CommonStockMember 2019-12-31 0001213809 us-gaap:TreasuryStockMember 2019-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001213809 us-gaap:RetainedEarningsMember 2019-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001213809 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001213809 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001213809 us-gaap:CommonStockMember 2020-06-30 0001213809 us-gaap:TreasuryStockMember 2020-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001213809 us-gaap:RetainedEarningsMember 2020-06-30 0001213809 2018-12-31 0001213809 2019-06-30 0001213809 dyai:IndustrialTechnologyBusinessMember dyai:DaniscoUSAMember 2015-12-31 2015-12-31 dyai:scientist dyai:segment dyai:customer 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-06-30 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2019-12-31 2019-12-31 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2020-01-01 2020-06-30 xbrli:pure 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:NonUsMember 2020-06-30 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:NonUsMember 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:NonUsMember 2019-12-31 2019-12-31 0001213809 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:NonUsMember 2019-12-31 0001213809 us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2020-04-01 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2019-04-01 2019-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2020-01-01 2020-06-30 0001213809 us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2019-01-01 2019-06-30 0001213809 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2020-06-30 0001213809 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2020-06-30 2020-06-30 0001213809 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2019-12-31 0001213809 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember dyai:ContractResearchOrganizationsMember 2019-12-31 2019-12-31 0001213809 us-gaap:BilledRevenuesMember 2020-06-30 0001213809 us-gaap:BilledRevenuesMember 2019-12-31 0001213809 us-gaap:UnbilledRevenuesMember 2020-06-30 0001213809 us-gaap:UnbilledRevenuesMember 2019-12-31 0001213809 us-gaap:TaxYear2018Member 2020-01-01 2020-06-30 0001213809 us-gaap:CashMember 2020-06-30 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001213809 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001213809 us-gaap:CashMember 2019-12-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001213809 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2020-04-01 2020-06-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-04-01 2019-06-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-06-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-06-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-12-31 0001213809 2017-06-30 2017-06-30 iso4217:EUR 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:VLPbioMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MinimumMember dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2018-03-31 0001213809 dyai:NovovetMember 2019-04-26 0001213809 dyai:AlphazymeMember 2020-06-24 2020-06-24 dyai:antibody_and_vaccine 0001213809 us-gaap:CollaborativeArrangementMember dyai:SerumMember 2019-05-07 dyai:protein 0001213809 us-gaap:CollaborativeArrangementMember dyai:SerumMember 2019-05-07 2019-05-07 utr:sqft 0001213809 dyai:JupiterFloridaHeadquartersLeaseMember 2020-06-30 0001213809 dyai:JupiterFloridaHeadquartersLeaseMember 2020-01-01 2020-06-30 0001213809 dyai:NetherlandsOfficeLeaseMember 2020-01-01 2020-06-30 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-06-28 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-06-28 2019-06-28 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-10-25 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-10-25 2019-10-25 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2020-03-23 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2020-03-23 2020-03-23 0001213809 dyai:A2006PlanMember 2020-06-30 0001213809 dyai:A2011PlanMember 2020-06-30 0001213809 dyai:A2011PlanMember 2020-01-01 2020-01-01 0001213809 dyai:A2011PlanMember 2019-01-01 2019-01-01 0001213809 dyai:A2011PlanMember 2019-12-31 0001213809 dyai:A2011PlanMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001213809 dyai:A2011PlanMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember srt:ChiefExecutiveOfficerMember 2020-01-01 2020-06-30 0001213809 dyai:ContractorMember dyai:A2011PlanMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-06-30 0001213809 dyai:ContractorMember dyai:A2011PlanMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-06-30 0001213809 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001213809 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001213809 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-06-30 0001213809 2019-12-31 2019-12-31 0001213809 2020-01-01 2020-03-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:ExecutivesandKeyPersonnelMember 2020-01-02 2020-01-02 0001213809 dyai:ExecutivesandKeyPersonnelMember 2020-01-02 2020-01-02 0001213809 srt:DirectorMember 2020-01-02 2020-01-02 0001213809 dyai:EmployeeMember 2020-01-02 2020-01-02 0001213809 dyai:EmployeeMember us-gaap:EmployeeStockOptionMember 2020-01-02 2020-01-02 0001213809 dyai:ConsultantMember us-gaap:EmployeeStockOptionMember 2020-01-02 2020-01-02 0001213809 dyai:ConsultantMember 2020-01-02 2020-01-02 0001213809 dyai:ContractorMember us-gaap:EmployeeStockOptionMember 2020-03-22 0001213809 dyai:ContractorMember 2020-03-22 2020-03-22 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001213809 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-03-31 0001213809 us-gaap:TreasuryStockMember 2020-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001213809 us-gaap:RetainedEarningsMember 2020-03-31 0001213809 2020-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001213809 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001213809 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001213809 us-gaap:CommonStockMember 2018-12-31 0001213809 us-gaap:TreasuryStockMember 2018-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001213809 us-gaap:RetainedEarningsMember 2018-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001213809 2019-01-01 2019-03-31 0001213809 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001213809 us-gaap:CommonStockMember 2019-03-31 0001213809 us-gaap:TreasuryStockMember 2019-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001213809 us-gaap:RetainedEarningsMember 2019-03-31 0001213809 2019-03-31 0001213809 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001213809 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001213809 us-gaap:CommonStockMember 2019-06-30 0001213809 us-gaap:TreasuryStockMember 2019-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001213809 us-gaap:RetainedEarningsMember 2019-06-30 0001213809 us-gaap:TaxYear2019Member us-gaap:SubsequentEventMember 2020-07-27 2020-07-27 0001213809 dyai:OpenMarketSaleAgreementMember us-gaap:SubsequentEventMember 2020-08-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the quarterly period ended June 30, 2020
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the transition period from _____ to ______

Commission File Number: 000-55264
DYADIC INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware |  | 45-0486747
State or Other Jurisdiction of Incorporation or Organization |  | I.R.S. Employer Identification No.
140 Intracoastal Pointe Drive, Suite 404 Jupiter, Florida |  | 33477
Address of Principal Executive Offices |  | Zip Code

(561) 743-8333

| Registrant’s Telephone Number, Including Area Code |  |  |
|  | N/A |  |

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ |  |  |  | Accelerated filer ☐ |
Non-accelerated filer ☒ |  |  |  | Smaller reporting company ☒ |
|  |  |  | Emerging growth company ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | DYAI | The NASDAQ Stock Market LLC

The number of shares outstanding of each of the registrant’s Common Stock as of August 12, 2020 was 27,482,157.

TABLE OF CONTENTS |  |
|  | Page
PART I FINANCIAL INFORMATION |  |
Item 1. | Financial Statements | 3
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 23
Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 30
Item 4. | Controls and Procedures | 30
PART II OTHER INFORMATION |  | 31
Item 1. | Legal Proceedings | 31
Item 1A. | Risk Factors | 31
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 32
Item 3. | Defaults Upon Senior Securities | 32
Item 4. | Mine Safety Disclosures | 32
Item 5. | Other Information | 32
Item 6. | Exhibits | 33
Signatures |  | 34

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Information (other than historical facts) set forth in this Quarterly Report contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 2 “Management’s Discussion and Analysis”. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors within and/or beyond Dyadic’s control. These factors include, but are not limited to (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties’ research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on our key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform; (9) the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd; (10) speculative nature and illiquidity of equity securities received as consideration from sub-licenses; (11) the impact of the novel coronavirus identified as “COVID-19” on our business and operating results; and (12) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in this Form 10-Q and our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption “Risk Factors” in this Form 10-Q and elsewhere in our Form 10-K filed with the SEC on March 30, 2020 which could have a material adverse effect on our business, results of operations and financial condition.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.
We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
PART I

Item 1. | Financial Statements

3

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

| June 30, 2020 |  | December 31, 2019
| (Unaudited) |  | (Audited)
Assets |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 11,781,549 |  |  | $ | 4,823,544 |
Short-term investment securities | 20,053,019 |  |  | 29,399,146 |
Interest receivable | 226,135 |  |  | 329,711 |
Accounts receivable | 564,672 |  |  | 558,530 |
Income tax receivable | 500,616 |  |  | 250,308 |
Prepaid expenses and other current assets | 599,514 |  |  | 277,999 |
Total current assets | 33,725,505 |  |  | 35,639,238 |
Non-current assets: |  |  |
Long-term investment securities | — |  |  | 1,511,636 |
Long-term income tax receivable | — |  |  | 250,308 |
Other assets | 6,116 |  |  | 51,314 |
Total assets | $ | 33,731,621 |  |  | $ | 37,452,496 |
Liabilities and stockholders’ equity |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 1,143,961 |  |  | $ | 943,378 |
Accrued expenses | 378,124 |  |  | 566,003 |
Provision for contract losses | 74,955 |  |  | — |
Deferred research and development obligations | 41,376 |  |  | 78,644 |
Total current liabilities | 1,638,416 |  |  | 1,588,025 |
Commitments and contingencies (Note 4) |  |  |
Stockholders’ equity: |  |  |
Preferred stock, $.0001 par value: |  |  |
Authorized shares - 5,000,000; none issued and outstanding | — |  |  | — |
Common stock, $.001 par value: |  |  |
Authorized shares - 100,000,000; issued shares - 39,735,659 and 39,612,659, outstanding shares - 27,482,157 and 27,359,157 as of June 30, 2020 and December 31, 2019, respectively | 39,736 |  |  | 39,613 |
Additional paid-in capital | 97,200,023 |  |  | 96,105,851 |
Treasury stock, shares held at cost - 12,253,502 | (18,929,915) |  |  | (18,929,915) |
Accumulated deficit | (46,216,639) |  |  | (41,351,078) |
Total stockholders’ equity | 32,093,205 |  |  | 35,864,471 |
Total liabilities and stockholders’ equity | $ | 33,731,621 |  |  | $ | 37,452,496 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.
4

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

|  | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
|  | 2020 |  | 2019 |  | 2020 |  | 2019
Revenues: |  |  |  |  |  |  |  |
Research and development revenue |  | $ | 524,271 |  |  | $ | 390,874 |  |  | $ | 839,643 |  |  | $ | 793,401 |
Costs and expenses: |  |  |  |  |  |  |  |
Costs of research and development revenue |  | 624,240 |  |  | 322,228 |  |  | 902,422 |  |  | 650,131 |
Provision for contract losses |  | 74,955 |  |  | — |  |  | 74,955 |  |  | — |
Research and development |  | 1,116,163 |  |  | 818,240 |  |  | 1,871,616 |  |  | 1,510,610 |
Research and development - related party |  | — |  |  | 336,310 |  |  | — |  |  | 725,783 |
General and administrative |  | 1,475,232 |  |  | 1,870,678 |  |  | 3,128,624 |  |  | 3,298,745 |
Foreign currency exchange loss (gain), net |  | 31,690 |  |  | 4,932 |  |  | 42,557 |  |  | 10,966 |
Total costs and expenses |  | 3,322,280 |  |  | 3,352,388 |  |  | 6,020,174 |  |  | 6,196,235 |
Loss from operations |  | (2,798,009) |  |  | (2,961,514) |  |  | (5,180,531) |  |  | (5,402,834) |
Interest income |  | 146,587 |  |  | 265,722 |  |  | 314,970 |  |  | 532,684 |
Loss before income taxes |  | (2,651,422) |  |  | (2,695,792) |  |  | (4,865,561) |  |  | (4,870,150) |
Provision for income taxes |  | — |  |  | — |  |  | — |  |  | 900 |
Net loss |  | $ | (2,651,422) |  |  | $ | (2,695,792) |  |  | $ | (4,865,561) |  |  | $ | (4,871,050) |
Basic and diluted net loss per common share |  | $ | (0.10) |  |  | $ | (0.10) |  |  | $ | (0.18) |  |  | $ | (0.18) |
Basic and diluted weighted-average common shares outstanding |  | 27,467,366 |  |  | 26,828,754 |  |  | 27,459,415 |  |  | 26,771,439 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.
5

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)

| Common Stock |  |  |  | Treasury Stock |  |  |  | Additional |  | Accumulated |  |
| Shares |  | Amount |  | Shares |  | Amount |  | Paid-in Capital |  | Deficit |  | Total
Balance at December 31, 2019 | 39,612,659 |  |  | $ | 39,613 |  |  | (12,253,502) |  |  | $ | (18,929,915) |  |  | $ | 96,105,851 |  |  | $ | (41,351,078) |  |  | $ | 35,864,471 |
Stock-based compensation | — |  |  | — |  |  | — |  |  | — |  |  | 863,552 |  |  | — |  |  | 863,552 |
Exercise of stock options | 123,000 |  |  | 123 |  |  | — |  |  | — |  |  | 230,620 |  |  | — |  |  | 230,743 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (4,865,561) |  |  | (4,865,561) |
Balance at June 30, 2020 | 39,735,659 |  |  | $ | 39,736 |  |  | (12,253,502) |  |  | $ | (18,929,915) |  |  | $ | 97,200,023 |  |  | $ | (46,216,639) |  |  | $ | 32,093,205 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.
6

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| Six Months Ended June 30, |  |
| 2020 |  | 2019
Cash flows from operating activities |  |  |
Net loss | $ | (4,865,561) |  |  | $ | (4,871,050) |
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
Stock-based compensation expense | 863,552 |  |  | 890,166 |
Amortization of held-to-maturity securities, net | 229,919 |  |  | 90,785 |
Provision for contract losses | 74,955 |  |  | — |
Foreign currency exchange loss (gain), net | 50,204 |  |  | 10,966 |
Changes in operating assets and liabilities: |  |  |
Interest receivable | 103,576 |  |  | (105,002) |
Accounts receivable | 32,112 |  |  | (189,246) |
Income tax receivable | — |  |  | 506,866 |
Prepaid research and development | — |  |  | 154,522 |
Prepaid expenses and other current assets | (321,533) |  |  | 59,867 |
Accounts payable | 154,484 |  |  | 665,126 |
Accrued expenses | (188,369) |  |  | (3,535) |
Deferred research and development obligation | (37,268) |  |  | (50,430) |
Net cash used in operating activities | (3,903,929) |  |  | (2,840,965) |
Cash flows from investing activities |  |  |
Purchases of held-to-maturity investment securities | (14,677,156) |  |  | (23,571,163) |
Proceeds from maturities of investment securities | 25,305,000 |  |  | 28,676,000 |
Net cash provided by investing activities | 10,627,844 |  |  | 5,104,837 |
Cash flows from financing activities |  |  |
Proceeds from exercise of options | 230,743 |  |  | 149,180 |
Net cash provided by financing activities | 230,743 |  |  | 149,180 |
Effect of exchange rate changes on cash | 3,347 |  |  | (17,846) |
Net increase in cash and cash equivalents | 6,958,005 |  |  | 2,395,206 |
Cash and cash equivalents at beginning of period | 4,823,544 |  |  | 2,386,314 |
Cash and cash equivalents at end of period | $ | 11,781,549 |  |  | $ | 4,781,520 |
Supplemental cash flow information |  |  |
Cash received from income tax refund | $ | — |  |  | $ | 506,866 |

The accompanying notes are an integral part of these unaudited consolidated financial statements.
7

Notes to Consolidated Financial Statements
Note 1: Organization and Summary of Significant Accounting Policies
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies designed to leverage its C1 technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters.
Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.
Impact of COVID-19
The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees, operations, and research projects.
To date, as a direct result of COVID-19, most of our employees are working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the response to curb its spread, currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.
8

The Company is currently working on several COVID-19 related vaccine and antibody opportunities, including but not limited to the following:
•The Company was selected by the Frederick National Laboratory to engineer Dyadic’s patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.
•Israel Institute for Biologic Research (“IIBR”) is exploring the potential of Dyadic’s industrially proven C1 gene expression platform to express a recombinant SARS-CoV-2 vaccine candidate based on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The interim results of the mice trials using the C1 SARS-CoV-2 RBD vaccine candidate. as reported to Dyadic by IIBR, generated high neutralizing antibody titers. Accordingly, we anticipate that the IIBR will start hamster studies earlier than originally forecasted.
•Collaboration with three scientists who are a part of the EU ZAPI initiative: Dr. Bosch at Utrecht University (UU), Dr. Haagmans at Erasmus Medical Center (EMC), and Prof. Osterhaus at University of Veterinary Medicine Hannover, DE (TiHo), and Mr. Es-Sbai at CR20 a clinical contract research organization to pre-clinically and clinically evaluate SARS-CoV-2 Receptor Binding Domain vaccine candidates to respond to the COVID-19 pandemic.
•Collaboration with Ufovax, a spin-off vaccine company of Scripps Research.
•On August 10, 2020, the Company entered into another fully funded SARS-CoV-2 vaccine research collaboration.
•The Company is in discussions with and is pursuing a number of other opportunities where it may be able to apply its C1 gene expression platform to help combat the COVID-19 pandemic.
We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that we have sufficient cash, cash equivalents and investments to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. The company may decide to fund all or part of a Phase I clinical trial in order to demonstrate the safety of the C1 expression platform in humans. There is no assurance that funding would be available at acceptable terms, if at all.
Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2019, included in our Form 10-K which was filed with the SEC on March 30, 2020.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates
9

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
Concentrations and Credit Risk
The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
For the three months ended June 30, 2020 and 2019, the Company’s revenue was generated from nine and four customers, respectively. For the six months ended June 30, 2020 and 2019, the Company’s revenue was generated from ten and seven customers, respectively. As of June 30, 2020 and December 31, 2019, the Company’s accounts receivable was from eight and five customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
The Company generates a portion of its revenues from customers that are located outside of the United States. For the three and six months ended June 30, 2020, the Company had four and five customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 49.2% or $258,000, and 52.5% or $441,000 of total revenue, respectively. For the three and six months ended June 30, 2019, the company had two customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 73.3% or $287,000 and 71.5% or $567,000 of total revenue, respectively.
As of June 30, 2020, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 55.6% or $289,000 of accounts receivable. As of December 31, 2019, the Company had four customers outside of the United States that accounted for approximately 69.5% or $388,000 of accounts receivable.
The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the three months ended June 30, 2020 and 2019, one CRO accounted for approximately 96.9% and 72.7% of total research services we purchased, respectively. For the six months ended June 30, 2020 and 2019, one CRO accounted for approximately 98.0% and 83.4% of total research services we purchased, respectively. As of June 30, 2020, approximately $1,050,000 or 91.8% of accounts payable was related to this CRO. As of December 31, 2019, approximately $706,000 or 74.9% of accounts payable was related to this CRO. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.
Cash and Cash Equivalents
We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.
Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of June 30, 2020 and December 31, 2019, all
10

of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of June 30, 2020 or December 31, 2019.
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of June 30, 2020 and December 31, 2019.
Accounts receivable consist of the following:

| June 30, 2020 |  | December 31, 2019
| (Unaudited) |  | (Audited)
Billed receivable | $ | 402,076 |  |  | $ | 432,546 |
Unbilled receivable | 162,596 |  |  | 125,984 |
| $ | 564,672 |  |  | $ | 558,530 |

Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:

| June 30, 2020 |  | December 31, 2019
| (Unaudited) |  | (Audited)
Prepaid insurance | $ | 416,199 |  |  | $ | 173,890 |
Prepaid expenses - various | 166,334 |  |  | 101,221 |
Prepaid research and development | 16,261 |  |  | — |
Prepaid taxes | 720 |  |  | 2,888 |
| $ | 599,514 |  |  | $ | 277,999 |

Accounts Payable
Accounts payable consist of the following:

| June 30, 2020 |  | December 31, 2019
| (Unaudited) |  | (Audited)
Research and development expenses | $ | 1,050,481 |  |  | $ | 766,001 |
Legal expenses | 5,903 |  |  | 26,994 |
Other | 87,577 |  |  | 150,383 |
| $ | 1,143,961 |  |  | $ | 943,378 |

Accrued Expenses
Accrued expenses consist of the following:
11

| June 30, 2020 |  | December 31, 2019
| (Unaudited) |  | (Audited)
Employee wages and benefits | $ | 285,133 |  |  | $ | 474,388 |
Research and development expenses | 38,711 |  |  | 69,795 |
Other | 54,280 |  |  | 21,820 |
| $ | 378,124 |  |  | $ | 566,003 |

Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants and fundings: The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations. These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting
12

guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.
Research and Development Costs
Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three and six months ended June 30, 2020 and 2019 were as follows:

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
| (Unaudited) |  | (Unaudited) |  | (Unaudited) |  | (Unaudited)
Outside contracted services | $ | 970,846 |  |  | $ | 658,499 |  |  | $ | 1,584,636 |  |  | $ | 1,243,986 |
Contracted services - related party | — |  |  | 336,310 |  |  | — |  |  | 725,783 |
Personnel related costs | 139,515 |  |  | 122,290 |  |  | 263,153 |  |  | 217,052 |
Facilities, overhead and other | 5,802 |  |  | 37,451 |  |  | 23,827 |  |  | 49,572 |
| $ | 1,116,163 |  |  | $ | 1,154,550 |  |  | $ | 1,871,616 |  |  | $ | 2,236,393 |

Provision for Contract Losses
The Company assesses the profitability of our collaboration agreements to provide research services to our contracted business partners and identifies those contracts where current operating results or forecasts indicate probable future losses. If an anticipated contract cost exceeds anticipated contract revenue, a provision for the entire estimated loss on the contract is recorded and then accreted into the statement of operations over the remaining term of the contract. The provision for contract losses is based on judgment and estimates, including revenues and costs, where applicable, the consideration of our business partners’ reimbursement, and when such loss is deemed probable to occur and is reasonable to estimate.
Foreign Currency Transaction Gain or Loss
The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
13

Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2019.
The TCJA repealed the corporate AMT but permitted unused AMT credit carryforwards to be used to reduce the regular tax obligation in future years. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Subsequently, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), which was signed into law in March 2020, accelerated the full refund of any unused AMT credits from 2021 (as provided for in the TCJA) to 2018 or 2019, at the taxpayer’s election.
Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of June 30, 2020, we have received 50% or approximately a $0.5 million refund for tax year 2018.
For the six months ended June 30, 2020, there were no provision for income taxes and unrecognized tax benefits recorded.
Deferred tax assets as of June 30, 2020 and December 31, 2019 were approximately $7.6 million and $7.2 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of June 30, 2020 and December 31, 2019.
On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. On June 16, 2020, the Company received the final closing letter from the IRS, informing the Company that its review of our tax filing for 2016 was complete, and no changes were required.
14

Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.
Stock-Based Compensation
We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.
For the three and six months ended June 30, 2020 and 2019, the effect of the potential exercise of options to purchase 4,650,390 and 4,108,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
Recent Accounting Pronouncements Not Adopted as of June 30, 2020
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The ASU became effective for the Company beginning in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Note 2: Cash, Cash Equivalent, and Investments
The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of June 30, 2020 and December 31, 2019:
15

| June 30, 2020 (Unaudited) |  |  |  |  |  |  |  |
|  |  |  |  | Gross |  | Gross |  |
| Level |  |  |  | Unrealized |  | Unrealized |  |
| (1) |  | Fair Value |  | Holding Gains |  | Holding Losses |  | Adjusted Cost
Cash and Cash Equivalents |  |  |  |  |  |  |  |  |
Cash |  |  | $ | 258,470 |  |  | $ | — |  |  | $ | — |  |  | $ | 258,470 |
Money Market Funds | 1 |  | 11,523,079 |  |  | — |  |  | — |  |  | 11,523,079 |
Subtotal |  |  | 11,781,549 |  |  | — |  |  | — |  |  | 11,781,549 |
Short-Term Investment Securities (2) |  |  |  |  |  |  |  |  |
Corporate Bonds (4) | 2 |  | 20,145,612 |  |  | 96,852 |  |  | (4,259) |  |  | 20,053,019 |
Total |  |  | $ | 31,927,161 |  |  | $ | 96,852 |  |  | $ | (4,259) |  |  | $ | 31,834,568 |

| December 31, 2019 (Audited) |  |  |  |  |  |  |  |
|  |  |  |  | Gross |  | Gross |  |
| Level |  |  |  | Unrealized |  | Unrealized |  |
| (1) |  | Fair Value |  | Holding Gains |  | Holding Losses |  | Adjusted Cost
Cash and Cash Equivalents |  |  |  |  |  |  |  |  |
Cash |  |  | $ | 1,010,510 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,010,510 |
Money Market Funds | 1 |  | 3,813,034 |  |  | — |  |  | — |  |  | 3,813,034 |
Subtotal |  |  | 4,823,544 |  |  | — |  |  | — |  |  | 4,823,544 |
Short-Term Investment Securities (2) |  |  |  |  |  |  |  |  |
Corporate Bonds (4) | 2 |  | 29,387,053 |  |  | 5,898 |  |  | (17,991) |  |  | 29,399,146 |
Long-Term Investment Securities (3) |  |  |  |  |  |  |  |  |
Corporate Bonds (4) | 2 |  | 1,528,190 |  |  | 16,554 |  |  | — |  |  | 1,511,636 |
Total |  |  | $ | 35,738,787 |  |  | $ | 22,452 |  |  | $ | (17,991) |  |  | $ | 35,734,326 |

_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $24,771 and $23,308 for the three months ended June 30, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $221,156 and $104,163 for the six months ended June 30, 2020 and 2019, respectively. The premium paid to purchase held-to-maturity investment securities was $233,550 for the year ended December 31, 2019.
The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of June 30, 2020, the Company does not consider any of its investments to be other-than-temporarily impaired.
Note 3: Research Collaboration and Sub-licensing Agreements
BDI Agreements
16

On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”).
The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.
Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share or EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.
The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results.
The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1 million paid by Dyadic were expensed as the related research services were performed by BDI. In June 2019, BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. As of December 31, 2019, Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA. However, the Company may in the future continue to provide funding to BDI for certain research and commercialization projects.
As of June 30, 2020 and December 31, 2019, there were $0.02 million and none, respectively, in prepaid expenses and other current assets related to BDI. For the three months ended June 30, 2020, and 2019, research and development expenses related to BDI recorded as research and development - related party in our consolidated statements of operations were none and approximately $0.3 million, respectively. For the six months ended June 30, 2020, and 2019, research and development expenses related to BDI were none and approximately $0.7 million, respectively.
Novovet and Luina Bio Sub-License Agreement
On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.
In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder
17

Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform.
The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.
As of June 30, 2020, Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.
Alphazyme Sub-License Agreement
On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.
On June 24, 2020, the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the “Amended Sub-License Agreement”) with Alphazyme to amend and restate the Alphazyme Sub-License Agreement.
Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic’s transfer of its C1 technology, Alphazyme is obligated to issue the Company 2.5% of the Class A shares of Alphazyme, and Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform.
The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the cost method, given that it does not have the ability to exercise significant influence or control over Alphazyme. No revenue from the Alphazyme Sub-Licensing Agreement was recorded during the six months ended June 30, 2020 because the amount of consideration received was immaterial.
Research and Commercialization Collaboration with Serum Institute of India
On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
For the three months ended June 30, 2020, the Company recognized approximately $99,260 in research and research revenue from Serum. For the six months ended June 30, 2020, the Company recognized approximately $174,632 in research and research revenue from Serum.
Note 4: Commitments and Contingencies
Leases
18

Jupiter, Florida Headquarters
The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700 in total. The current office lease, which expired on June 30, 2020, is being extended on a monthly basis. The Company is currently negotiating a new lease to reconsider the square footage of the space to align with the future operations of the Company.
The Netherlands Office
The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies a flexible office space for an annual rental rate of approximately $4,000. The lease expires on January 31, 2021, and thereafter, the Company will reconsider the leased space to align with the future operations of the Company.
VTT Research Contract Extension
On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. On March 23, 2020, the Company further expanded the Contract to pay an additional EUR €700,000 over the next 19 months to accelerate the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.
Legal Proceedings
We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.
Note 5: Share-Based Compensation
Description of Equity Plans
The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019 and 2020.
As of June 30, 2020, the Company had 4,650,390 stock options outstanding and an additional 2,134,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2019, there were 3,860,390 stock options outstanding and 1,547,211 shares of common stock available for grant under the 2011 Plan.
Stock Options
19

Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is ten years except for certain options granted to the CEO (five years) and contractors (two or three years).
The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:
Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.
Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.
Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.
Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for certain options granted to the CEO (five years) and contractors (two or three years).
The assumptions used in the Black-Scholes option pricing model for stock options granted during the six months ended June 30, 2020 are as follows:

Risk-Free interest rate | 0.25% - 1.72%
Expected dividend yield | — | %
Expected stock price volatility | 39.94% - 51.22%
Expected life of options | 1.75 - 6.25 Years

The following table summarizes the stock option activities during the six months ended June 30, 2020:

| Shares |  | Weighted-Average Exercise Price |  | Weighted-Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Outstanding at December 31, 2019 | 3,860,390 |  |  | $1.76 |  | 5.7 |  | $13,287,932
Granted (1) | 913,000 |  |  | 5.24 |  |  |  |  |
Exercised (2) | (123,000) |  |  | 1.88 |  |  |  |  |
Expired | — |  |  | — |  |  |  |  |
Canceled | — |  |  | — |  |  |  |  |
Outstanding at June 30, 2020 | 4,650,390 |  |  | $2.44 |  | 6.1 |  | $28,939,039
Exercisable at June 30, 2020 | 3,250,294 |  |  | $1.76 |  | 5.0 |  | $22,413,471

_________________
Notes:
(1) Represents the following stock options granted:
20

•Annual share-based compensation awards on January 2, 2020, including: (a) 525,000 stock options with an exercise price of $5.27 per share granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 325,000 stock options with an exercise price of $5.27 per share granted to the Board of Directors, vesting upon one year anniversary, (c) 23,000 stock options with an exercise price of $5.27 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $5.27 per share granted to a consultant, vesting upon one year anniversary.
•One-time awards on March 22, 2020, including 25,000 stock options to a contractor with an exercise price of $3.99 per share, vesting in six months from the date of grant.
(2) Represents the following stock options exercised:
•A total of 123,000 stock options exercised with a weighted average exercise price of $1.88.
Compensation Expenses
We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Total non-cash stock option compensation expense was allocated among the following expense categories:

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
General and administrative | $ | 390,702 |  |  | $ | 555,455 |  |  | $ | 770,953 |  |  | $ | 839,089 |
Research and development | 45,912 |  |  | 25,148 |  |  | 92,599 |  |  | 51,077 |
Total | $ | 436,614 |  |  | $ | 580,603 |  |  | $ | 863,552 |  |  | $ | 890,166 |

Note 6: Shareholders’ Equity
Issuances of Common Stock
For the six months ended June 30, 2020, there were 123,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.88 per share. For the six months ended June 30, 2019, there were 397,671 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.59 per share.
Changes in Stockholders Equity
21

|  | Six Months Ended June 30, 2020 (Unaudited) |  |  |  |  |  |  |  |
|  | Common Stock |  | Treasury Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Total
January 1, 2020 |  | $ | 39,613 |  |  | $ | (18,929,915) |  |  | $ | 96,105,851 |  |  | $ | (41,351,078) |  |  | $ | 35,864,471 |
Stock-based compensation |  | — |  |  | — |  |  | 426,939 |  |  | — |  |  | 426,939 |
Exercise of stock options |  | 100 |  |  | — |  |  | 174,900 |  |  | — |  |  | 175,000 |
Net loss |  | — |  |  | — |  |  | — |  |  | (2,214,139) |  |  | (2,214,139) |
March 31, 2020 |  | $ | 39,713 |  |  | $ | (18,929,915) |  |  | $ | 96,707,690 |  |  | $ | (43,565,217) |  |  | $ | 34,252,271 |
Stock issued |  | — |  |  | — |  |  | 436,613 |  |  | — |  |  | 436,613 |
Stock-based compensation |  | 23 |  |  | — |  |  | 55,720 |  |  | — |  |  | 55,743 |
Net loss |  | — |  |  | — |  |  | — |  |  | (2,651,422) |  |  | (2,651,422) |
June 30, 2020 |  | $ | 39,736 |  |  | $ | (18,929,915) |  |  | $ | 97,200,023 |  |  | $ | (46,216,639) |  |  | $ | 32,093,205 |
|  | Six Months Ended June 30, 2019 (Unaudited) |  |  |  |  |  |  |  |
|  | Common Stock |  | Treasury Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Total
January 1, 2019 |  | $ | 38,967 |  |  | $ | (18,929,915) |  |  | $ | 94,385,230 |  |  | $ | (33,043,113) |  |  | $ | 42,451,169 |
Stock-based compensation |  | — |  |  | — |  |  | 309,563 |  |  | — |  |  | 309,563 |
Net loss |  | — |  |  | — |  |  | — |  |  | (2,175,258) |  |  | (2,175,258) |
March 31, 2019 |  | $ | 38,967 |  |  | $ | (18,929,915) |  |  | $ | 94,694,793 |  |  | $ | (35,218,371) |  |  | $ | 40,585,474 |
Stock issued |  | 398 |  |  | — |  |  | 148,782 |  |  | — |  |  | 149,180 |
Stock-based compensation |  | — |  |  | — |  |  | 580,603 |  |  | — |  |  | 580,603 |
Net loss |  | — |  |  | — |  |  | — |  |  | (2,695,792) |  |  | (2,695,792) |
June 30, 2019 |  | $ | 39,365 |  |  | $ | (18,929,915) |  |  | $ | 95,424,178 |  |  | $ | (37,914,163) |  |  | $ | 38,619,465 |

Treasury Stock
As of June 30, 2020 and December 31, 2019, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.
Note 7: Subsequent Events
Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.
On July 27, 2020, we received the remaining $0.5 million AMT refund for tax year 2019 pursuant to the CARES Act.
Open Market Sale Agreement℠
On August 13, 2020, we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.
We are not obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.
22

The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-3 that will be filed with the U.S. Securities and Exchange Commission (“SEC”) on August 13, 2020, if and when that registration statement is declared effective. The offering will be described in our Prospectus dated and filed the date the registration statement is declared effective by the SEC, as supplemented by a Prospectus Supplement.
For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through August 13, 2020, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in “Item 1A. Risk Factors” in this Quarterly Report. All forward-looking statements included in this Quarterly Report are based on information available to us as of the time we file this Quarterly Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.
Overview
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies designed to leverage its C1 technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters.
Recent Developments
23

In the first half of fiscal 2020, the Company continued to develop relationships with business and research partners in the biopharmaceutical industry and achieved the following:
•Data presented at the 15th European Conference on Fungal Genetics (“ECFG15”) demonstrated that C1 strain has been glyco-engineered to achieve a core human-like G2 glycan level over 76%. Data also showed excellent progress we made in reducing the extracellular protease background by 50 times in C1. The elimination of protease activity makes the C1 cell line more efficient at producing stable proteins, leading to even higher expression levels and lower cost.
•Dyadic entered into two additional funded collaborations with two top four animal health companies to engage in a feasibility study regarding the production of their target proteins using our C1 platform. The Company has now entered into fully funded collaborations with each of the top four animal health companies to evaluate C1. The first two projects with one of these top four have been expanded with additional funding and have entered the second phase of development.
•Dyadic entered into a nonexclusive research license with WuXi Biologics, one of the leading global Contract Development and Manufacturing Organizations.
•Dyadic entered into a new feasibility study with the University of Oslo on influenza vaccine.
•In July, Dyadic entered into a new, fully-funded collaboration with another top five global pharmaceutical company.
Impact of COVID-19
The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees, operations, and research projects.
To date, as a direct result of COVID-19, most of our employees are working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the response to curb its spread, currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.
The Company is currently working on several COVID-19 related vaccine and antibody opportunities, including but not limited to the following:
•The Company was selected by the Frederick National Laboratory to engineer Dyadic’s patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.
•Israel Institute for Biologic Research (“IIBR”) is exploring the potential of Dyadic’s industrially proven C1 gene expression platform to express a recombinant SARS-CoV-2 vaccine candidate based on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The interim results of the mice trials using the C1 SARS-CoV-2 RBD vaccine candidate. as reported to Dyadic by IIBR, generated high neutralizing antibody titers. Accordingly, we anticipate that the IIBR will start hamster studies earlier than originally forecasted.
24

•Collaboration with three scientists who are a part of the EU ZAPI initiative: Dr. Bosch at Utrecht University (UU), Dr. Haagmans at Erasmus Medical Center (EMC), and Prof. Osterhaus at University of Veterinary Medicine Hannover, DE (TiHo), and Mr. Es-Sbai at CR20 a clinical contract research organization to pre-clinically and clinically evaluate SARS-CoV-2 Receptor Binding Domain vaccine candidates to respond to the COVID-19 pandemic.
•Collaboration with Ufovax, a spin-off vaccine company of Scripps Research.
•In the second quarter of 2020, the Company entered into another fully funded SARS-CoV-2 vaccine research collaboration.
We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that we have sufficient cash, cash equivalents and investments to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. The company may decide to fund all or part of a Phase I clinical trial in order to demonstrate the safety of the C1 expression platform in humans. There is no assurance that funding would be available at acceptable terms, if at all.
Critical Accounting Policies, Estimates, and Judgments
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:
Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will
25

be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants and fundings:The Company may receive grants and fundings from governments, agencies, and other private and not-for-profit organizations.These grants and fundings are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which sales-based royalties relate, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.
Provision for Contract Losses
The Company assesses the profitability of our collaboration agreements to provide research services to our contracted business partners and identifies those contracts where current operating results or forecasts indicate probable future losses. If the anticipated contract cost exceeds the anticipated contract revenue, a provision for the entire estimated loss on the contract is recorded and then accreted into the statement of operations over the remaining term of the contract. The provision for contract losses is based on judgment and estimates, including revenues and costs, where applicable, the consideration of our business partners’ reimbursement, and when such loss is deemed probable to occur and is reasonable to estimate.
Accrued Research and Development Expenses
In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the
26

associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.
Stock-Based Compensation
We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to the Company April 2019 uplisting to NASDAQ. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option except in the case of our CEO, 5 or 10 years , and in the case of contractors, 2 or 3 years). The Company performs a review of assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company’s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure. The change in assumption was effective January 1, 2018 and only impacts new options granted in 2018 and thereafter.
The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.
In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.
Accounting for Income Taxes
The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740 (“Topic 740”), “Income Taxes”. Under this method, income tax expense/(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.
In determining taxable income for the Company’s consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.
The Company is required to evaluate the provisions of Topic 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 prescribes a comprehensive model for how a company should
27

recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of Topic 740.
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The legislation included, among other things, a reduction of the U.S. federal corporate income tax rate from 35% to 21%, and a repeal of the corporate alternative minimum tax (the “AMT”). The TCJA repealed the corporate AMT but permitted unused AMT credit carryforwards to be used to reduce the regular tax obligation in future years. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Subsequently, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), which was signed into law in March 2020, accelerated the full refund of any unused AMT credits from 2021 (as provided for in the TCJA) to 2018 or 2019, at the taxpayer’s election .
Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of June 30, 2020, we have received 50% or approximately a $0.5 million refund for tax year 2018. On July 27, 2020, we received the remaining $0.5 million AMT refund for the tax year 2019.
Fair Value Measurements
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
The Company bases its fair value estimates on assumptions it believes to be reasonable, but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Recent Accounting Pronouncements
See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements.
Results of Operations
Three and Six Months Ended June 30, 2020 Compared to the Same Periods in 2019
Revenue, Cost of Revenue, and Provision for Contract Losses
The following table summarizes the Company’s revenue, cost of research and development revenue and provision for contract losses for the three and six months ended June 30, 2020 and 2019:
28

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, 2020 |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Revenue | $ | 524,271 |  |  | $ | 390,874 |  |  | $ | 839,643 |  |  | $ | 793,401 |
Cost of research and development revenue | 624,240 |  |  | 322,228 |  |  | 902,422 |  |  | 650,131 |
Provision for contract losses | 74,955 |  |  | — |  |  | 74,955 |  |  | — |

The increase in revenue and cost of research and development revenue for the three months ended June 30, 2020 reflected nine on-going research collaborations compared to four collaborations for the same period a year ago. The increase in revenue and cost of research and development revenue for the six months ended June 30, 2020 reflected ten on-going research collaborations compared to seven collaborations for the same period a year ago. The increase in provision for contract losses reflected the activities of one biopharmaceutical collaboration research project.
Research and Development Expenses
Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs.
Research and development expenses for the three months ended June 30, 2020 increased to approximately $1,116,000 compared to $818,000 for the same period a year ago. The increase primarily reflected the costs of additional internal research projects.
Research and development expenses for the six months ended June 30, 2020 increased to approximately $1,872,000 compared to $1,511,000 for the same period a year ago. The increase primarily reflected the costs of additional internal research projects.
Research and development expenses - related party, for the three months ended June 30, 2020, was none compared to approximately $336,000 for the same period a year ago. The decrease was due to the completion of the Research Service Agreement with BDI in June 2019.
Research and development expenses - related party, for the six months ended June 30, 2020, was none compared to approximately $726,000 for the same period a year ago. The decrease was due to the completion of the Research Service Agreement with BDI in June 2019.
General and Administrative Expenses
General and administrative expenses for the three months ended June 30, 2020, decreased 21.2% to approximately $1,475,000 compared to $1,871,000 for the same period a year ago. The decrease principally reflected reductions in noncash share-based compensation expenses of $165,000, executive compensation costs and accrued incentives of $150,000, legal and NASDAQ uplisting expenses of $102,000, business development and investor relations costs, including travel expenses of $24,000, offset by increases in insurance premium and outside service costs of $45,000.
General and administrative expenses for the six months ended June 30, 2020, decreased 5.2% to approximately $3,129,000 compared to $3,299,000 for the same period a year ago. The decrease principally reflected reductions in executive compensation costs and accrued incentives of $220,000, legal and NASDAQ uplisting expenses of $125,000, noncash share-based compensation expenses of $68,000, offset by increases in insurance premium of $147,000, business development and investor relations costs of $47,000 and other increases of $49,000.
Interest Income
Interest income for the three months ended June 30, 2020 was approximately $147,000 compared to $266,000 for the same period a year ago. The decrease was primarily due to the lower interest rate and yield on the Company’s investment grade securities, which are classified as held-to-maturity.
Interest income for the six months ended June 30, 2020 was approximately $315,000 compared to $533,000 for the same period a year ago. The decrease was primarily due to the lower interest rate and yield on the Company’s investment grade securities, which are classified as held-to-maturity.
29

Net Loss
Net loss for the three months ended June 30, 2020 was approximately $2,651,000 compared to $2,696,000 for the same period a year ago.
Net loss for the six months ended June 30, 2020 was approximately $4,866,000 compared to $4,871,000 for the same period a year ago.
Liquidity and Capital Resources
Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, interest income received from investment grade securities, and funding from our research collaboration agreements. Between January 2016 and August 2018, the Company repurchased a total of 14,390,254 shares of its common stock from its existing cash on hand, for an aggregate purchase price of $21,814,530 at a weighted average price of $1.52 per share. As of June 30, 2020, our investment balance includes $20.3 million of short-term investments with contractual maturities of twelve (12) months of less, including interest receivable. The Company’s liquidity was further improved with the receipt of an approximately $0.5 million tax refund in June 2019 and an approximately $0.5 million additional tax refund in July 2020 resulting from the elimination of corporate Alternative Minimum Tax (AMT) under the TCJA.
Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sub-license agreements. We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities, including our business development and research expenses, as well as additional costs as an SEC reporting and NASDAQ listed company. We believe that our existing cash position and investments in short-term and long-term investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months.
As of June 30, 2020, cash and cash equivalents were approximately $11.8 million compared to $4.8 million as of December 31, 2019. The carrying value of short-term and long-term investment grade securities, including accrued interest as of June 30, 2020 was approximately $20.3 million compared to $31.2 million as of December 31, 2019.
Net cash used in operating activities for the six months ended June 30, 2020 of approximately $3.9 million was principally attributable to a net loss of approximately $4.9 million and changes in operating assets and liabilities of approximately $0.3 million, offset by share-based compensation expenses of approximately $0.9 million, amortization of held-to-maturity securities of approximately $0.2 million, and other items of approximately $0.2 million.
Net cash used in operating activities for the six months ended June 30, 2019 of approximately $2.8 million was principally attributable to a net loss of $4.9 million, partially offset by share-based compensation expense of approximately $0.9 million, changes in tax receivable of approximately $0.5 million, changes in other operating assets and liabilities of approximately $0.5 million, and amortization of held-to-maturity securities of approximately $0.1 million.
Net cash provided by investing activities for the six months ended June 30, 2020 was approximately $10.6 million compared to $5.1 million for the six months ended June 30, 2019. Cash flows from investing activities during the six months ended June 30, 2020 and 2019 were primarily related to proceeds from maturities and purchases of investment grade debt securities.
Net cash provided by financing activities for the six months ended June 30, 2020 was approximately $0.2 million compared to $0.1 million for the six months ended June 30, 2019. Cash flows from financing activities during the six months ended June 30, 2020 and 2019 were primarily related to proceeds from exercise of options.

Item 3. | Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. | Controls and procedures

30

Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the six months ended June 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.
Inherent Limitation on Effectiveness of Controls
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
PART II

Item 1. | Legal Proceedings

We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

Item 1A. | Risk Factors

There have been no changes to our risk factors from those disclosed in our Form 10-K for the 2019 fiscal year filed on March 30, 2020, other than the updated risk factors set forth below.
We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious disease, pandemics, epidemics or other biological threats, such as the ongoing COVID-19 pandemic, that could significantly disrupt our operations and have a material adverse effect on our business, employees, directors, consultants, collaborators and other third parties, including business development activities and research and development projects conducted by third party contract research organizations parties.
31

Significant outbreaks of contagious diseases, and other adverse public health developments, could have a material impact on our business operations, financial condition, and operating results. The ongoing COVID-19 pandemic has significantly impacted the operation of business in the United States and Europe, where several of our key executive management members and our third-party contract research organizations are located. The continuation of the COVID-19 pandemic and various governmental responses in the United States and Europe has adversely affected and may continue to adversely affect our business operations, including our ability to carry on business development activities, restrictions in business-related travel, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, among others.
In addition, we rely on third parties in the United States and Europe to conduct our research and development projects and to provide other services, and COVID-19 has affected and may continue to affect service providers of such third-party contract research organizations and therefore negatively affect the operations of our on-going research projects, which could materially and negatively affect our business, financial condition, and results of operations.
The COVID-19 pandemic has adversely affected and may continue to adversely affect the economies and financial markets worldwide, resulting in an economic downturn that could impact our business, financial condition and results of operations. As a result, our ability to fund through public or private equity offerings, debt financings, and through other means at acceptable terms, if at all, may be disrupted, in the event our financing needs for the foreseeable future are not able to be met by our existing balances of cash, cash equivalents and investments. The extent to which COVID-19 could impact our business and research and development activities will depend on future developments, which are highly uncertain and cannot be predicted with confidence, and will depend on many factors, including the duration of the outbreak, the effect of travel restrictions and social distancing efforts in the United States and other countries, the scope and length of business closures or business disruptions, and the actions taken by governments to contain and treat the disease. As such, we cannot presently predict the scope and extent of any potential business shutdowns or disruptions.
The Company is currently working on several COVID-19 related vaccine and antibody opportunities. However, there is no assurance that any of these opportunities will materialize or that the C1 technology or any product expressed from C1 or any of the various other steps in a vaccine or drug development process will perform, provide benefits, obtain governmental safety and regulatory approvals, be registered or gain market acceptance. In addition, our C1 technology has yet to be used to produce a vaccine, antibody or other biologic product that has entered the clinical trial phase, and we are competing with more experienced companies for grants or funding of this type. As a result, there is no assurance that we will receive these grants or funding resulting from these proposals.

Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. | Defaults Upon Senior Securities

Not applicable.

Item 4. | Mine Safety Disclosures

Not applicable.

Item 5. | Other Information

Open Market Sale Agreement℠
32

On August 13, 2020, we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.
We are not obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.
The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-3 that will be filed with the U.S. Securities and Exchange Commission (“SEC”) on August 13, 2020, if and when that registration statement is declared effective. The offering will be described in our Prospectus dated and filed the date the registration statement is declared effective by the SEC, as supplemented by a Prospectus Supplement.
We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies' counsel, if required. The sale agreement will terminate upon the sale of all $50.0 million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.
The sale agreement will be filed as an exhibit to the registration statement on Form S-3 to be filed with the SEC on August 13, 2020.
This Quarterly Report on Form 10-Q shall not constitute an offer to sell or the solicitation of an offer to buy any shares of our common stock under the sale agreement nor shall there be any offer, solicitation or sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 6. | Exhibits

Following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

|  |  |  | Incorporated by Reference |  |  |  |  |  |
Exhibit No. |  | Description of Exhibit |  | Form |  | Original No. |  | Date Filed |  | Filed Herewith
10.1 |  | Amended and Restated Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated June 24, 2020 |  | 8-K |  | 10.1 |  | June 29, 2020 |  |
31.1 |  | Certification of Principal Executive Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  | x
31.2 |  | Certification of Principal Financial Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  | x
32.1 |  | Certification of Principal Executive Officer of Dyadic Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  | x
32.2 |  | Certification of Principal Financial Officer of Dyadic Pursuant to18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  | x

33

Exhibit No. |  | Description
101.INS |  | XBRL Instance Document
101.SCH |  | XBRL Taxonomy Extension Schema Document
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | XBRL Taxonomy Extension Labels Linkbase Document
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| DYADIC INTERNATIONAL, INC. |
August 13, 2020 | By: | /s/ Mark A. Emalfarb
|  | Mark A. Emalfarb
|  | President and Chief Executive Officer
|  | (Principal Executive Officer)
August 13, 2020 | By: | /s/ Ping W. Rawson
|  | Ping W. Rawson
|  | Chief Financial Officer
|  | (Principal Financial Officer and Principal Accounting Officer)

34